Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer Academic Article uri icon


MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Prostate-Specific Antigen
  • Prostatic Neoplasms
  • Radioimmunotherapy


  • Despite recent advances, advanced prostate cancer is suboptimally responsive to current chemotherapeutic agents. Radiolabeled monoclonal antibody therapy that targets prostate-specific membrane antigen (PSMA) shows promise and is an area of active investigation. J591 is a deimmunized IgG monoclonal antibody developed to target the extracellular domain of PSMA. Preclinical and early phase clinical studies using radiolabeled J591 have demonstrated efficacy in targeting tumor cells and decreasing levels of prostate-specific antigen. Radiolabeled J591 is well-tolerated, nonimmunogenic, and can be administered in multiple doses. The dose-limiting toxicity is reversible myelosuppression with little nonhematologic toxicity. Future studies will include approaches to optimize patient selection and incorporate novel strategies to improve the success of anti-PSMA radioimmunotherapy.

publication date

  • February 15, 2010



  • Academic Article



  • eng

PubMed Central ID

  • PMC2820151

Digital Object Identifier (DOI)

  • 10.1002/cncr.24795

PubMed ID

  • 20127956

Additional Document Info

start page

  • 1075

end page

  • 83


  • 116


  • SUPPL. 4